Loading…

Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: Systematic review of randomized controlled trials

Several reviews of randomized controlled trials (RCTs) have shown the efficacy of mu-opioids in reducing spontaneous neuropathic pain (NP). However, relatively little is known about their specific efficacy for evoked pain, which is a significant problem for many patients with NP. The present systema...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pain 2006-11, Vol.10 (8), p.667-667
Main Authors: Eisenberg, Elon, McNicol, Ewan D., Carr, Daniel B.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5397-1d83ba870040ebba163dd27e74d8ceeb22133cb4a4d6fb0f5d5baa8fcc7d135c3
cites cdi_FETCH-LOGICAL-c5397-1d83ba870040ebba163dd27e74d8ceeb22133cb4a4d6fb0f5d5baa8fcc7d135c3
container_end_page 667
container_issue 8
container_start_page 667
container_title European journal of pain
container_volume 10
creator Eisenberg, Elon
McNicol, Ewan D.
Carr, Daniel B.
description Several reviews of randomized controlled trials (RCTs) have shown the efficacy of mu-opioids in reducing spontaneous neuropathic pain (NP). However, relatively little is known about their specific efficacy for evoked pain, which is a significant problem for many patients with NP. The present systematic review assesses the efficacy of opioid agonists for the treatment of evoked NP based upon published RCTs. We searched articles in any language using the MEDLINE database (1966 to December 2004), the Cochrane Central Register of Controlled Trials (4th quarter, 2004) and the reference lists of retrieved papers, employing search terms for RCTs, opioids and NP. Only RCTs in which opioid agonists were given to treat NP of any etiology, and evoked pain was assessed were included. Data were extracted by two independent investigators. Nine articles met inclusion criteria and were classified as short-term (less than 24 h; n = 7) or intermediate-term trials (4 weeks; n = 2). Although the scarcity of retrieved data precluded formal meta-analysis of short-term trials, we found that the intensity of dynamic mechanical allodynia was significantly attenuated by opioids relative to placebo in all studies. In contrast, no consistent effects on the magnitude of static allodynia, the threshold for mechanical allodynia or the threshold or magnitude of heat allodynia were found. The threshold and magnitude of cold-induced allodynia generally responded positively to opioid treatments in patients with peripheral pain syndromes, but not central pain syndromes. Evoked pain was studied in only two intermediate-term trials, in both of which oxycodone was significantly superior to placebo. The results of the two trials were combinable for a meta-analysis that showed an overall 24 points difference in endpoint pain intensities between patients given opioids and those treated with placebo (95% CI −33 to −15; p < 0.00001). In conclusion: short-term studies show that opioids can reduce the intensity of dynamic mechanical allodynia and perhaps of cold allodynia in peripheral NP. Insufficient evidence precludes drawing conclusions regarding the effect of opioids on other forms of evoked NP. A meta-analysis of intermediate-term studies demonstrates the efficacy of opioids over placebo for evoked NP. These findings are clinically relevant because dynamic mechanical allodynia and cold allodynia are the most prevalent types of evoked pain in NP.
doi_str_mv 10.1016/j.ejpain.2005.10.007
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68897957</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S109038010500159X</els_id><sourcerecordid>68897957</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5397-1d83ba870040ebba163dd27e74d8ceeb22133cb4a4d6fb0f5d5baa8fcc7d135c3</originalsourceid><addsrcrecordid>eNqNkUFv1DAQhS0EoqXlHyDkE7csdhzHCQckVG23VCtAaiskLpZjT6i3SRxsp2WR-t9xlBXcEKcZjb73NPMGoVeUrCih5dvdCnajssMqJ4Sn0YoQ8QQdU87yLKdF_TT1pCYZqwg9Qi9C2BFCCkHYc3RES8YE5fQYPa7b1mql99i1uJ8yN1pnDVbf3WBDDNgOON4Cjh5U7GGIMwb37g4MHmDyblTx1mo8L_IOX-1DhF7FNPBwb-Fhpr0ajOvtr6TQbojedV1qo7eqC6foWZsKvDzUE3Rzvr4-u8i2nzcfzz5sM81ZLTJqKtaoSqT9CTSNSusbkwsQhak0QJPnlDHdFKowZduQlhveKFW1WgtDGdfsBL1ZfEfvfkwQouxt0NB1agA3BVlWVS1qLhJYLKD2LgQPrRy97ZXfS0rkHLvcySV2Occ-T1PsSfb64D81PZi_okPOCagX4MF2sP8vU7m-_JKXxWyeLdr0EPj5R6v8nSwFE1x-_bSRl9tvF-fXdCNn_v3CQ0o0fcHLoC0MGoz1oKM0zv77mt-zLroj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68897957</pqid></control><display><type>article</type><title>Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: Systematic review of randomized controlled trials</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Eisenberg, Elon ; McNicol, Ewan D. ; Carr, Daniel B.</creator><creatorcontrib>Eisenberg, Elon ; McNicol, Ewan D. ; Carr, Daniel B.</creatorcontrib><description>Several reviews of randomized controlled trials (RCTs) have shown the efficacy of mu-opioids in reducing spontaneous neuropathic pain (NP). However, relatively little is known about their specific efficacy for evoked pain, which is a significant problem for many patients with NP. The present systematic review assesses the efficacy of opioid agonists for the treatment of evoked NP based upon published RCTs. We searched articles in any language using the MEDLINE database (1966 to December 2004), the Cochrane Central Register of Controlled Trials (4th quarter, 2004) and the reference lists of retrieved papers, employing search terms for RCTs, opioids and NP. Only RCTs in which opioid agonists were given to treat NP of any etiology, and evoked pain was assessed were included. Data were extracted by two independent investigators. Nine articles met inclusion criteria and were classified as short-term (less than 24 h; n = 7) or intermediate-term trials (4 weeks; n = 2). Although the scarcity of retrieved data precluded formal meta-analysis of short-term trials, we found that the intensity of dynamic mechanical allodynia was significantly attenuated by opioids relative to placebo in all studies. In contrast, no consistent effects on the magnitude of static allodynia, the threshold for mechanical allodynia or the threshold or magnitude of heat allodynia were found. The threshold and magnitude of cold-induced allodynia generally responded positively to opioid treatments in patients with peripheral pain syndromes, but not central pain syndromes. Evoked pain was studied in only two intermediate-term trials, in both of which oxycodone was significantly superior to placebo. The results of the two trials were combinable for a meta-analysis that showed an overall 24 points difference in endpoint pain intensities between patients given opioids and those treated with placebo (95% CI −33 to −15; p &lt; 0.00001). In conclusion: short-term studies show that opioids can reduce the intensity of dynamic mechanical allodynia and perhaps of cold allodynia in peripheral NP. Insufficient evidence precludes drawing conclusions regarding the effect of opioids on other forms of evoked NP. A meta-analysis of intermediate-term studies demonstrates the efficacy of opioids over placebo for evoked NP. These findings are clinically relevant because dynamic mechanical allodynia and cold allodynia are the most prevalent types of evoked pain in NP.</description><identifier>ISSN: 1090-3801</identifier><identifier>EISSN: 1532-2149</identifier><identifier>DOI: 10.1016/j.ejpain.2005.10.007</identifier><identifier>PMID: 16337151</identifier><language>eng</language><publisher>Oxford, UK: Elsevier Ltd</publisher><subject>Allodynia ; Analgesics, Opioid - therapeutic use ; Humans ; Hyperalgesia ; Neuralgia - drug therapy ; Neuralgia - etiology ; Quantitative sensory testing ; Randomized Controlled Trials as Topic ; Receptors, Opioid, mu - agonists ; Treatment Outcome</subject><ispartof>European journal of pain, 2006-11, Vol.10 (8), p.667-667</ispartof><rights>2005 European Federation of Chapters of the International Association for the Study of Pain</rights><rights>2006 European Federation of Chapters of the International Association for the Study of Pain</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5397-1d83ba870040ebba163dd27e74d8ceeb22133cb4a4d6fb0f5d5baa8fcc7d135c3</citedby><cites>FETCH-LOGICAL-c5397-1d83ba870040ebba163dd27e74d8ceeb22133cb4a4d6fb0f5d5baa8fcc7d135c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16337151$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eisenberg, Elon</creatorcontrib><creatorcontrib>McNicol, Ewan D.</creatorcontrib><creatorcontrib>Carr, Daniel B.</creatorcontrib><title>Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: Systematic review of randomized controlled trials</title><title>European journal of pain</title><addtitle>Eur J Pain</addtitle><description>Several reviews of randomized controlled trials (RCTs) have shown the efficacy of mu-opioids in reducing spontaneous neuropathic pain (NP). However, relatively little is known about their specific efficacy for evoked pain, which is a significant problem for many patients with NP. The present systematic review assesses the efficacy of opioid agonists for the treatment of evoked NP based upon published RCTs. We searched articles in any language using the MEDLINE database (1966 to December 2004), the Cochrane Central Register of Controlled Trials (4th quarter, 2004) and the reference lists of retrieved papers, employing search terms for RCTs, opioids and NP. Only RCTs in which opioid agonists were given to treat NP of any etiology, and evoked pain was assessed were included. Data were extracted by two independent investigators. Nine articles met inclusion criteria and were classified as short-term (less than 24 h; n = 7) or intermediate-term trials (4 weeks; n = 2). Although the scarcity of retrieved data precluded formal meta-analysis of short-term trials, we found that the intensity of dynamic mechanical allodynia was significantly attenuated by opioids relative to placebo in all studies. In contrast, no consistent effects on the magnitude of static allodynia, the threshold for mechanical allodynia or the threshold or magnitude of heat allodynia were found. The threshold and magnitude of cold-induced allodynia generally responded positively to opioid treatments in patients with peripheral pain syndromes, but not central pain syndromes. Evoked pain was studied in only two intermediate-term trials, in both of which oxycodone was significantly superior to placebo. The results of the two trials were combinable for a meta-analysis that showed an overall 24 points difference in endpoint pain intensities between patients given opioids and those treated with placebo (95% CI −33 to −15; p &lt; 0.00001). In conclusion: short-term studies show that opioids can reduce the intensity of dynamic mechanical allodynia and perhaps of cold allodynia in peripheral NP. Insufficient evidence precludes drawing conclusions regarding the effect of opioids on other forms of evoked NP. A meta-analysis of intermediate-term studies demonstrates the efficacy of opioids over placebo for evoked NP. These findings are clinically relevant because dynamic mechanical allodynia and cold allodynia are the most prevalent types of evoked pain in NP.</description><subject>Allodynia</subject><subject>Analgesics, Opioid - therapeutic use</subject><subject>Humans</subject><subject>Hyperalgesia</subject><subject>Neuralgia - drug therapy</subject><subject>Neuralgia - etiology</subject><subject>Quantitative sensory testing</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Receptors, Opioid, mu - agonists</subject><subject>Treatment Outcome</subject><issn>1090-3801</issn><issn>1532-2149</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqNkUFv1DAQhS0EoqXlHyDkE7csdhzHCQckVG23VCtAaiskLpZjT6i3SRxsp2WR-t9xlBXcEKcZjb73NPMGoVeUrCih5dvdCnajssMqJ4Sn0YoQ8QQdU87yLKdF_TT1pCYZqwg9Qi9C2BFCCkHYc3RES8YE5fQYPa7b1mql99i1uJ8yN1pnDVbf3WBDDNgOON4Cjh5U7GGIMwb37g4MHmDyblTx1mo8L_IOX-1DhF7FNPBwb-Fhpr0ajOvtr6TQbojedV1qo7eqC6foWZsKvDzUE3Rzvr4-u8i2nzcfzz5sM81ZLTJqKtaoSqT9CTSNSusbkwsQhak0QJPnlDHdFKowZduQlhveKFW1WgtDGdfsBL1ZfEfvfkwQouxt0NB1agA3BVlWVS1qLhJYLKD2LgQPrRy97ZXfS0rkHLvcySV2Occ-T1PsSfb64D81PZi_okPOCagX4MF2sP8vU7m-_JKXxWyeLdr0EPj5R6v8nSwFE1x-_bSRl9tvF-fXdCNn_v3CQ0o0fcHLoC0MGoz1oKM0zv77mt-zLroj</recordid><startdate>200611</startdate><enddate>200611</enddate><creator>Eisenberg, Elon</creator><creator>McNicol, Ewan D.</creator><creator>Carr, Daniel B.</creator><general>Elsevier Ltd</general><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200611</creationdate><title>Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: Systematic review of randomized controlled trials</title><author>Eisenberg, Elon ; McNicol, Ewan D. ; Carr, Daniel B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5397-1d83ba870040ebba163dd27e74d8ceeb22133cb4a4d6fb0f5d5baa8fcc7d135c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Allodynia</topic><topic>Analgesics, Opioid - therapeutic use</topic><topic>Humans</topic><topic>Hyperalgesia</topic><topic>Neuralgia - drug therapy</topic><topic>Neuralgia - etiology</topic><topic>Quantitative sensory testing</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Receptors, Opioid, mu - agonists</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eisenberg, Elon</creatorcontrib><creatorcontrib>McNicol, Ewan D.</creatorcontrib><creatorcontrib>Carr, Daniel B.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pain</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eisenberg, Elon</au><au>McNicol, Ewan D.</au><au>Carr, Daniel B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: Systematic review of randomized controlled trials</atitle><jtitle>European journal of pain</jtitle><addtitle>Eur J Pain</addtitle><date>2006-11</date><risdate>2006</risdate><volume>10</volume><issue>8</issue><spage>667</spage><epage>667</epage><pages>667-667</pages><issn>1090-3801</issn><eissn>1532-2149</eissn><abstract>Several reviews of randomized controlled trials (RCTs) have shown the efficacy of mu-opioids in reducing spontaneous neuropathic pain (NP). However, relatively little is known about their specific efficacy for evoked pain, which is a significant problem for many patients with NP. The present systematic review assesses the efficacy of opioid agonists for the treatment of evoked NP based upon published RCTs. We searched articles in any language using the MEDLINE database (1966 to December 2004), the Cochrane Central Register of Controlled Trials (4th quarter, 2004) and the reference lists of retrieved papers, employing search terms for RCTs, opioids and NP. Only RCTs in which opioid agonists were given to treat NP of any etiology, and evoked pain was assessed were included. Data were extracted by two independent investigators. Nine articles met inclusion criteria and were classified as short-term (less than 24 h; n = 7) or intermediate-term trials (4 weeks; n = 2). Although the scarcity of retrieved data precluded formal meta-analysis of short-term trials, we found that the intensity of dynamic mechanical allodynia was significantly attenuated by opioids relative to placebo in all studies. In contrast, no consistent effects on the magnitude of static allodynia, the threshold for mechanical allodynia or the threshold or magnitude of heat allodynia were found. The threshold and magnitude of cold-induced allodynia generally responded positively to opioid treatments in patients with peripheral pain syndromes, but not central pain syndromes. Evoked pain was studied in only two intermediate-term trials, in both of which oxycodone was significantly superior to placebo. The results of the two trials were combinable for a meta-analysis that showed an overall 24 points difference in endpoint pain intensities between patients given opioids and those treated with placebo (95% CI −33 to −15; p &lt; 0.00001). In conclusion: short-term studies show that opioids can reduce the intensity of dynamic mechanical allodynia and perhaps of cold allodynia in peripheral NP. Insufficient evidence precludes drawing conclusions regarding the effect of opioids on other forms of evoked NP. A meta-analysis of intermediate-term studies demonstrates the efficacy of opioids over placebo for evoked NP. These findings are clinically relevant because dynamic mechanical allodynia and cold allodynia are the most prevalent types of evoked pain in NP.</abstract><cop>Oxford, UK</cop><pub>Elsevier Ltd</pub><pmid>16337151</pmid><doi>10.1016/j.ejpain.2005.10.007</doi></addata></record>
fulltext fulltext
identifier ISSN: 1090-3801
ispartof European journal of pain, 2006-11, Vol.10 (8), p.667-667
issn 1090-3801
1532-2149
language eng
recordid cdi_proquest_miscellaneous_68897957
source Wiley-Blackwell Read & Publish Collection
subjects Allodynia
Analgesics, Opioid - therapeutic use
Humans
Hyperalgesia
Neuralgia - drug therapy
Neuralgia - etiology
Quantitative sensory testing
Randomized Controlled Trials as Topic
Receptors, Opioid, mu - agonists
Treatment Outcome
title Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: Systematic review of randomized controlled trials
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T18%3A21%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20mu-opioid%20agonists%20in%20the%20treatment%20of%20evoked%20neuropathic%20pain:%20Systematic%20review%20of%20randomized%20controlled%20trials&rft.jtitle=European%20journal%20of%20pain&rft.au=Eisenberg,%20Elon&rft.date=2006-11&rft.volume=10&rft.issue=8&rft.spage=667&rft.epage=667&rft.pages=667-667&rft.issn=1090-3801&rft.eissn=1532-2149&rft_id=info:doi/10.1016/j.ejpain.2005.10.007&rft_dat=%3Cproquest_cross%3E68897957%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5397-1d83ba870040ebba163dd27e74d8ceeb22133cb4a4d6fb0f5d5baa8fcc7d135c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=68897957&rft_id=info:pmid/16337151&rfr_iscdi=true